BioLife Solutions, Inc. (NASDAQ:BLFS) Short Interest Update

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) was the target of a large growth in short interest in the month of April. As of April 30th, there was short interest totalling 3,560,000 shares, a growth of 14.8% from the April 15th total of 3,100,000 shares. Based on an average trading volume of 390,800 shares, the short-interest ratio is currently 9.1 days.

Insiders Place Their Bets

In related news, CMO Todd Berard sold 10,000 shares of the company's stock in a transaction on Monday, April 15th. The shares were sold at an average price of $15.67, for a total value of $156,700.00. Following the completion of the transaction, the chief marketing officer now directly owns 129,644 shares in the company, valued at $2,031,521.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Amy Duross sold 6,135 shares of BioLife Solutions stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $16.86, for a total value of $103,436.10. Following the transaction, the director now owns 34,508 shares in the company, valued at approximately $581,804.88. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CMO Todd Berard sold 10,000 shares of the business's stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $15.67, for a total value of $156,700.00. Following the completion of the sale, the chief marketing officer now directly owns 129,644 shares of the company's stock, valued at approximately $2,031,521.48. The disclosure for this sale can be found here. Insiders have sold 33,996 shares of company stock worth $562,145 in the last three months. 2.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On BioLife Solutions

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Roubaix Capital LLC grew its holdings in shares of BioLife Solutions by 90.8% in the fourth quarter. Roubaix Capital LLC now owns 280,337 shares of the medical equipment provider's stock worth $4,555,000 after acquiring an additional 133,439 shares during the period. Huntington National Bank bought a new stake in shares of BioLife Solutions during the 3rd quarter valued at $1,697,000. Barclays PLC grew its holdings in BioLife Solutions by 205.3% during the third quarter. Barclays PLC now owns 56,968 shares of the medical equipment provider's stock valued at $787,000 after purchasing an additional 38,311 shares during the period. Millrace Asset Group Inc. bought a new position in shares of BioLife Solutions in the third quarter worth about $676,000. Finally, Meros Investment Management LP grew its stake in shares of BioLife Solutions by 14.7% during the 3rd quarter. Meros Investment Management LP now owns 372,203 shares of the medical equipment provider's stock valued at $5,140,000 after acquiring an additional 47,724 shares during the period. Hedge funds and other institutional investors own 93.24% of the company's stock.

BioLife Solutions Stock Up 8.6 %

BLFS stock traded up $1.77 during midday trading on Tuesday, hitting $22.43. The company's stock had a trading volume of 647,784 shares, compared to its average volume of 430,604. The firm's 50-day moving average is $17.64 and its 200-day moving average is $16.16. The company has a current ratio of 2.89, a quick ratio of 1.00 and a debt-to-equity ratio of 0.09. BioLife Solutions has a 12 month low of $8.92 and a 12 month high of $24.50. The company has a market cap of $1.02 billion, a PE ratio of -15.80 and a beta of 1.69.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last released its quarterly earnings data on Thursday, May 9th. The medical equipment provider reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.06. The company had revenue of $31.73 million for the quarter, compared to analysts' expectations of $29.30 million. BioLife Solutions had a negative return on equity of 12.89% and a negative net margin of 45.84%. During the same period last year, the firm posted ($0.27) earnings per share. On average, equities research analysts forecast that BioLife Solutions will post -0.6 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BLFS has been the subject of several research analyst reports. StockNews.com upgraded shares of BioLife Solutions to a "sell" rating in a report on Friday. Benchmark upgraded BioLife Solutions from a "neutral" rating to a "buy" rating and set a $25.00 price target on the stock in a research report on Monday. Finally, Jefferies Financial Group began coverage on shares of BioLife Solutions in a report on Thursday, April 4th. They set a "buy" rating and a $22.00 target price on the stock. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $23.67.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.